1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Bladder cancer

Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042

Awaiting development [GID-TA11592] Expected publication date: TBC

  • Project information
  • Project documents

28717-Sasanlimab-Bacillus-Calmette-Guerin-for-Bladder-Cancer-V1.0-APR2024-NON-CONF.pdf (nihr.ac.uk)